Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs

Life Sciences

Volumn 79, Issue 8, 2006, Pages 808-815

  Zhang, Wei Dong ^a,b   Zhang, Chuan ^a   Liu, Run Hui ^a   Li, Hui Liang ^a   Zhang, Jin Tao ^c   Mao, Chen ^c   Moran, Sara ^c   Chen, Chun Lin ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Medicilon Inc   (United States)

Author keywords

Astragaloside IV; HPLC MS MS; Pharmacokinetics

Indexed keywords

ASTRAGALOSIDE IV; NATURAL PRODUCT; PLASMA PROTEIN; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTRAGALUS MEMBRANACEUS; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIVER CLEARANCE; MALE; NONHUMAN; PLASMA PROTEIN BINDING; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANIMALS; BLOOD PROTEINS; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; MALE; MASS SPECTROMETRY; PROTEIN BINDING; RATS; SAPONINS; TISSUE DISTRIBUTION; TRITERPENES;

ASTRAGALUS MEMBRANACEUS; CANIS FAMILIARIS;

EID: 33745663269     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.02.032     Document Type: Article

References (17)

1. Chen C.L., Sangiah S., Bourne D.W.A., Roder J.D., Chen H., Alavi F.K., Clarke C.R., Garrison G.L., Berlin K.D., Couch K.M., Zisman S.A., Scherlag B.J., Lazzara R., and Helm D.V.D. Metabolism and metabolite pharmacokinetics of BRB-I-28, a novel antiarrhythmic agent. European Journal of Drug Metabolism and Pharmacokinetics 20 (1995) 151-161
2. Chen C.L., Tai H.L., Zhu D.M., and Uckun F.M. Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. Pharmaceutical Research 16 (1999) 1003-19009
3. Chen C.L., Rawwas J., Sorrell A., Eddy L., and Uckun F.M. Bioavailability and pharmacokinetic features of eEtoposide in childhood acute lymphoblastic leukemia patients. Leukemia and Lymphoma 42 (2001) 317-327
4. Chen C.L., Venkatachalam T.K., Zhu Z.H., and Uckun F.M. In vivo pharmacokinetics and metabolism of anti-HIV agent d4T-5′-[p-bromophenylmethoxyalaninyl phosphate] in mice. Drug Metabolism and Disposition 29 (2001) 1035-1041
5. Chen C.L., Yu G., Venkatachalam T.K., and Uckun F.M. Metabolism of stavudine 5′-[p-bromophenylmethoxyalaninyl phosphate], stampidine, in mice, dogs and cats. Drug Metabolism and Disposition 30 (2002) 1523-1531
6. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10 (1993) 1093-1095
7. Gabrielsson J., and Weiner D. Pharmacokinetic/Pharmacodynamic Data Analysis: Concept and Applications (1997), The Swedish Pharmaceutical Press, Apotekarsocieteten
8. Gu Y.C., and Wang G.J. Determination and pharmacokinetical study of astragaloside IV in rats urine by HPLC-MS. Journal of China Pharmaceutical University 33 (2002) 222-225
9. Gu Y.C., Wang G.J., Pan G., Fawcett J.P., and Sun J. Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali. C Basic and Clinical Pharmacology and Toxicology 95 (2004) 295-298
10. Li Z.P., and Cao Q. Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats. Acta Pharmacologica Sinica 23 (2002) 898-904
11. Lu S., Zhang J., and Yang D. Effects of astragaloside IV in treating myocardial injury and myocardial sarco/endoplasmic Ca(2+)-Atpase of viral myocarditis mice. Chinese Journal of Integrative Medicine 19 (1999) 672-674
12. Luo Y.M., Qin Z., Hong Z., Zhang X.M., Ding D., Fu J.H., Zhang W.D., and Chen J. Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neuroscience Letters 363 (2004) 218-223
13. Wang Y.P., Li X.Y., Song C.Q., and Hu Z.B. Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacologica Sinica 23 (2002) 263-266
14. Yang Q., Lu J.T., Zhou A.W., Wang B., He G.W., and Chen M.Z. Antinociceptive effect of astragalosides and its mechanism of action. Acta Pharmacologica Sinica 22 (2001) 809-812
15. Zhang Y.D., Shen J.P., Zhu S.H., Huang D.K., Ding Y., and Zhang X.L. Effects of astragalus (ASI, SK) on experimental liver injury. Acta Pharmaceutica Sinica 27 (1992) 401-406
16. Zhang W.J., Hufnagl P., Binder B.R., and Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-Kappab activation and adhesion molecule expression. Journal of Thrombosis and Haemostasis 90 (2003) 904-914
17. Zhang W.D., Zhang C., Liu R.H., Zhang J.T., Mao C., and Chen C.L. Quantitative determination of Astragaloside IV, a natural product with cardioprotective activity, in plasma, urine and other biological samples by HPLC coupled with tandem mass spectrometry. Journal of Chromatography B Analytic Technological Biomedical Life Sciences 822 (2005) 170-177